A federal securities fraud lawsuit now directly implicates thousands of ordinary investors who bought stock in ADMA Biologics, a New Jersey-based biopharmaceutical company. The case, filed in the U.S. District Court for the District of New Jersey, centers on allegations that the company and certain senior executives ran a hidden scheme to pump up revenue artificially. The bottom line for shareholders: the stock tanked, and the law firm Bleichmar Fonti & Auld LLP is now chasing recovery.
The lawsuit, known as Mazzarino v. ADMA Biologics, Inc., et al., No. 26-cv-6918, accuses the company of violating federal securities laws.
Specifically, the complaint cites Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Those provisions generally prohibit fraud and hold top executives liable for misleading statements that move markets. For investors, the core allegation is blunt.
The complaint claims ADMA engaged in a de facto channel stuffing scheme. That is a practice where a company pushes excessive product into its distribution pipeline—often by offering steep discounts or extended payment terms—to make sales look stronger than real demand.
The target, according to the suit, was ADMA’s flagship product, ASCENIV. ASCENIV is a liquid immune globulin solution. It treats Primary Humoral Immunodeficiency in adults and adolescents.
For the patients who rely on it, it is a critical therapy. For the company, it was supposed to be the revenue driver. The lawsuit alleges that, during the relevant period, ADMA was facing waning demand for ASCENIV.
Instead of reporting that truth, the company allegedly stuffed the channel to keep revenue figures up. The stock drop that followed was significant.
The lawsuit does not specify the exact percentage decline or the precise dollar amount of losses. But the drop was severe enough to trigger a class action. That means a lot of people lost a lot of money.
The law firm is now urging anyone who invested in ADMA securities to come forward. Investors have a hard deadline.
They must ask the Court to be appointed as lead plaintiff by August 10, 2026. That is the cutoff. Miss it, and you lose the right to steer the case.
The lead plaintiff typically is the investor or group with the largest financial stake. They represent the class. This is not a small, niche case.
ADMA Biologics is an end-to-end commercial biopharmaceutical company. It manufactures, markets, and develops specialty biologics.
That means it handles everything from lab to patient. The company is publicly traded. Its stock was held by ordinary retail investors, pension funds, and institutional players.
Those investors now face a choice. They can sit and wait.
Or they can contact Bleichmar Fonti & Auld to get more information. The law firm announced the lawsuit Monday and set up a website for inquiries. The case raises a practical question for people who buy stock in biotech firms.
How do you know if a company’s revenue is real or engineered? Channel stuffing is hard to detect from quarterly reports. It only becomes obvious when the pipeline backs up and orders collapse.
By then, the stock has already fallen. For now, the court will decide whether the allegations hold.
The complaint is just that—an accusation. But the clock is already running for investors who want a say in how the case proceeds. August 10, 2026, is the date to remember.
